Background: Interleukin-37 b(IL-37 b), a vital negative regulator of the innate immune system, has been reported to be a tumor inhibitor in different type of cancers. However, little is known about the relationship be...Background: Interleukin-37 b(IL-37 b), a vital negative regulator of the innate immune system, has been reported to be a tumor inhibitor in different type of cancers. However, little is known about the relationship between IL-37 b and hepatocellular carcinoma(HCC). The present study aimed to investigate the potential roles of IL-37 b in HCC progression. Methods: Subjects( n = 237) were recruited, and serum IL-37 b was measured using ELISA. The tumorsuppressive capacity and underlying mechanisms of IL-37 b in HCC were investigated in vitro and in vivo. Results: Compared to healthy controls, serum IL-37 b levels were elevated in chronic hepatitis B(CHB) patients but decreased significantly in HBV-HCC patients, especially for those with portal venous tumor thrombus. Low level serum IL-37 b in HBV-HCC patients correlated with high HCC stage and poor overall survival and disease-free survival. In vitro and in vivo, recombinant human IL-37 b inhibited proliferation and metastasis in HCC cells. Furthermore, IL-37 b inhibited epithelial mesenchymal transition in HCC cells in vitro by downregulating IL-6, pSTAT3(Y705), N-cadherin, and vimentin expression and by upregulating E-cadherin expression. These effects were partially reversed by transfection of adenovirus encoding human IL-6. Conclusions: IL-37 b inhibits HCC growth, metastasis and epithelial mesenchymal transition by regulating IL-6/STAT3 signaling. Serum IL-37 b may be a biomarker for HBV-HCC and its staging.展开更多
白细胞介素-1(IL-1)家族成员IL-1F7(IL-1 family 7)最近被命名为IL-37,它共有五种不同的亚型(IL-37a-e)。研究表明,IL-37b(IL-1F7b)可以与IL-18受体的α链结合,但并不影响IL-18的生理功能;IL-37b与IL-18结合蛋白(IL-18BP)结合后,可以增...白细胞介素-1(IL-1)家族成员IL-1F7(IL-1 family 7)最近被命名为IL-37,它共有五种不同的亚型(IL-37a-e)。研究表明,IL-37b(IL-1F7b)可以与IL-18受体的α链结合,但并不影响IL-18的生理功能;IL-37b与IL-18结合蛋白(IL-18BP)结合后,可以增强IL-18BP对IL-18的抑制作用。IL-37b的主要作用是抑制炎症反应,它在多种炎症相关性疾病中起重要作用。展开更多
基金supported by grants from the Scientific and Technological Research Program of Chongqing Municipal Education Commission(KJ1400220)the Basic Science and Frontier Technology Research Program of Chongqing Science and Technology Commission(cstc2017jcyjAX0224)
文摘Background: Interleukin-37 b(IL-37 b), a vital negative regulator of the innate immune system, has been reported to be a tumor inhibitor in different type of cancers. However, little is known about the relationship between IL-37 b and hepatocellular carcinoma(HCC). The present study aimed to investigate the potential roles of IL-37 b in HCC progression. Methods: Subjects( n = 237) were recruited, and serum IL-37 b was measured using ELISA. The tumorsuppressive capacity and underlying mechanisms of IL-37 b in HCC were investigated in vitro and in vivo. Results: Compared to healthy controls, serum IL-37 b levels were elevated in chronic hepatitis B(CHB) patients but decreased significantly in HBV-HCC patients, especially for those with portal venous tumor thrombus. Low level serum IL-37 b in HBV-HCC patients correlated with high HCC stage and poor overall survival and disease-free survival. In vitro and in vivo, recombinant human IL-37 b inhibited proliferation and metastasis in HCC cells. Furthermore, IL-37 b inhibited epithelial mesenchymal transition in HCC cells in vitro by downregulating IL-6, pSTAT3(Y705), N-cadherin, and vimentin expression and by upregulating E-cadherin expression. These effects were partially reversed by transfection of adenovirus encoding human IL-6. Conclusions: IL-37 b inhibits HCC growth, metastasis and epithelial mesenchymal transition by regulating IL-6/STAT3 signaling. Serum IL-37 b may be a biomarker for HBV-HCC and its staging.
文摘白细胞介素-1(IL-1)家族成员IL-1F7(IL-1 family 7)最近被命名为IL-37,它共有五种不同的亚型(IL-37a-e)。研究表明,IL-37b(IL-1F7b)可以与IL-18受体的α链结合,但并不影响IL-18的生理功能;IL-37b与IL-18结合蛋白(IL-18BP)结合后,可以增强IL-18BP对IL-18的抑制作用。IL-37b的主要作用是抑制炎症反应,它在多种炎症相关性疾病中起重要作用。
